Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of Baxdrostat (CIN-107) Tablet vs Solution
NCT05963009Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2020
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of baxdrostat in hypertension (HTN) (3 arms), sponsored by AstraZeneca. Primary endpoints: Incidence of Treatment Emergent Adverse Events, Maximum Concentration and 2 more. Started Mar 2020; status: completed.
02
Drugs
baxdrostat
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05963009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05963009.